Taurursodiol
drugOn this page
Also known as Tauroursodeoxycholic acidTauroursodesoxycholic acidTaurursodiol component of relyvrioUr-906UrsodeoxycholyltaurineUrsodoxicoltaurineUrsodeoxy cholic acidTauroursodeoxycholateTAUROURSODEOXY CHOLIC ACID DIHYDRATETauroursodeoxy cholic_acid dihydrateTauoursodeoxycholic acid
Summary
Taurursodiol (CHEMBL272427) is an approved small-molecule anti-inflammatory agent (ATC A05AA05); indicated across 2 conditions including neurodegenerative disease and amyotrophic lateral sclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A05AA05
- Indications: 2 conditions
- Clinical trials: 17
- Chemistry: 499.7 Da · C26H45NO6S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL272427 |
| Name | Taurursodiol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 9848818 |
| ChEBI | CHEBI:80774 |
| ATC | A05AA05 |
| Molecular formula | C26H45NO6S |
| Molecular weight | 499.7 |
| InChIKey | BHTRKEVKTKCXOH-LBSADWJPSA-N |
SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
IUPAC name: 2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
ChEBI definition: A bile acid taurine conjugate derived from ursoodeoxycholic acid.
Pharmacological roles (ChEBI): anti-inflammatory agent, neuroprotective agent, apoptosis inhibitor, cardioprotective agent, bone density conservation agent.
Other ChEBI roles (chemical / environmental): human metabolite.
Also known as: Tauroursodeoxycholic acid, Tauroursodesoxycholic acid, Taurursodiol, Taurursodiol component of relyvrio, Ur-906, Ursodeoxycholyltaurine, Ursodoxicoltaurine, Ursodeoxy cholic acid, ursodeoxy cholic acid, tauroursodeoxycholic acid, Tauroursodeoxycholate, TAUROURSODEOXY CHOLIC ACID DIHYDRATE
Patent coverage: 1,851 distinct patent families (4,753 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Bile acid receptor, Ileal sodium/bile acid cotransporter, Autotaxin, Phospholipase A2, G-protein coupled bile acid receptor 1.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ENPP2 | 7.98 | IC50 | 10.4 | nM | CHEMBL_ACT_29180045 |
| PLA2G1B | 5 | Kd | 10000 | nM | CHEMBL_ACT_2668845 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neurodegenerative disease | 1 | MONDO:0005559 | EFO:0005772 |
| amyotrophic lateral sclerosis | 1 | MONDO:0004976 | MONDO:0004976 |
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE3 | 4 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01998451 | PHASE4 | UNKNOWN | The Discovery of the Double Sphincter in Gallbladder |
| NCT01857284 | PHASE3 | COMPLETED | Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis |
| NCT03481972 | PHASE3 | COMPLETED | A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin |
| NCT03800524 | PHASE3 | UNKNOWN | Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS |
| NCT05753852 | PHASE3 | UNKNOWN | Open Label Extension of TUDCA-ALS Study |
| NCT07457632 | PHASE2 | NOT_YET_RECRUITING | Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine. |
| NCT01171859 | PHASE2 | COMPLETED | Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis |
| NCT01855360 | PHASE1/PHASE2 | COMPLETED | Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy |
| NCT03423121 | PHASE1/PHASE2 | COMPLETED | A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis |
| NCT03878654 | PHASE1 | TERMINATED | Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma |
| NCT04727320 | EARLY_PHASE1 | UNKNOWN | The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis. |
| NCT00004410 | Not specified | COMPLETED | Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants |
| NCT00004441 | Not specified | COMPLETED | Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis |
| NCT00771901 | Not specified | COMPLETED | Effect of Endoplasmic Reticulum Stress on Metabolic Function |
| NCT01877551 | Not specified | COMPLETED | Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance |
| NCT03331432 | Not specified | COMPLETED | Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function |
| NCT03462940 | Not specified | TERMINATED | Effects of TUDCA on Endothelial Function in Type 2 DM |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.